Seroprevalence of Hepatitis E in People With an Organ Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

447 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-12

Study Completion Date

2019-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant. They found that hepatitis E may not go away by itself in these people. It becomes chronic. This can cause serious liver disease. More than half the people who had organ transplant who had hepatitis E seemed to get a chronic infection.

Researchers want to find out if hepatitis E happens this often in patients who have liver, kidney, or small bowel transplants in the United States. If it does, they want to know why. They want to know if chronic hepatitis E will become an important medical problem. This research might help improve care for people who have a transplant. It also might help researchers prevent the spread of hepatitis E.

Objective:

\- To see how many patients who have received or are waiting for certain transplants have antibodies to hepatitis E virus.

Eligibility:

\- Adults over age 18 who have had a liver, kidney, liver and kidney, or small bowel transplant, or are on a waiting list for one.

Design:

* Participants will be enrolled from 3 transplant centers.
* Participants will complete a questionnaire. They will be asked about possible risk factors for hepatitis E exposure.
* Participants will have a blood sample drawn through a needle placed in a vein.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Retrospective Review of Infections Usually Observed in Transplant Recipients

NCT00298077

Infection

COMPLETED

Organ Transplant Infection Prevention and Detection Project

NCT00177801

Transplantation Infection

COMPLETED

Covid Vaccination in Liver Transplantation

NCT05079165

COVID-19

UNKNOWN

HCV + to HCV - Kidney Transplant

NCT04320290

Kidney Failure Hepatitis C

WITHDRAWN PHASE4

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00904579

Immunocompromised Host Organ Transplantation Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatitis E virus infection commonly presents as an acute self-limiting hepatitis in the developing world. However there have been reports that chronic hepatitis E may develop in immunocompromised subjects such as renal and liver transplant recipients. Progression to cirrhosis has also been reported in patients with chronic hepatitis E infection. We hypothesize that immunosuppression post-organ transplantation predisposes individuals to increased susceptibility to hepatitis E infection. Therefore, in this study, we wish to determine the seroprevalence of antibody to hepatitis E IgG in organ transplant recipients (an immunosuppressed population) and compare it to patients who are on organ transplant waitlist (not immunosuppressed). We plan to study samples and date from 300 organ transplant recipients and 300 patients on waitlist for liver, kidney or intestinal transplantation and control for age, gender, organ and transplant center. Three transplant centers (2 in the mid-Atlantic area and one in the Mid-West) will each enroll 100 cases and controls. A minimum of 50 cases at each site will be liver transplant recipients. Cases will be stratified based on number of years post transplant one, two or greater than or equal to three years. Consecutive patients who are eligible and agree to participate in the study will be enrolled. A brief questionnaire to assess risk factors for acquisition of hepatitis E will be administered and 8mls of blood will be drawn in a serum separator tube for anti HEV IgG, anti HEV IgM and HEV RNA testing analysis at the NIH. Subjects who are confirmed to have acute or chronic HEV infection will be managed according to standard of care at each respective transplant centers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis E

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Organ transplant recipients

Recipients of either liver, kidney, liver and kidney, and small bowel transplants

No interventions assigned to this group

Waitlist patients

Patients on waitlist for liver, kidney or intestinal transplantation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 18 years, male or female
* Recipients of either liver, kidney, liver and kidney, and small bowel transplants
* Survival for a minimum of 1 year post-transplant
* Willingness to provide written, informed consent

* Age greater than or equal to 18 years, male or female
* Subjects on the waitlist for first liver, kidney, liver and kidney or small bowel transplant
* Willingness to provide written, informed consent

Exclusion Criteria

* Current or previous treatment within the last year with peg-interferon and or ribavirin.
* Known history of hepatitis E infection.

* Current or previous treatment within the last year with peg-interferon and or ribavirin.
* Current immunosuppression
* Known history of hepatitis E infection.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No